Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections

Michael Cohen-Wolkowiez, Brenda Poindexter, Margarita Bidegain, Joern Hendrik Weitkamp, Robert L. Schelonka, David A. Randolph, Robert M. Ward, Kelly Wade, Gloria Valencia, David Burchfield, Antonio Arrieta, Varsha Mehta, Michele Walsh, Anand Kantak, Maynard Rasmussen, Janice E. Sullivan, Neil Finer, Wade Rich, Beverly S. Brozanski, John Van Den AnkerJeffrey Blumer, Matthew Laughon, Kevin M. Watt, Gregory L. Kearns, Edmund V. Capparelli, Karen Martz, Katherine Berezny, Daniel K. Benjamin, P. Brian Smith

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background.Intra-abdominal infections are common in young infants and lead to significant morbidity and mortality. Meropenem is a broad-spectrum antimicrobial with excellent activity against pathogens associated with intra-abdominal infections. The purpose of this study was to determine the safety and effectiveness of meropenem in young infants with suspected or complicated intra-abdominal infections.Methods.Preterm and term infants <91 days of age with suspected or confirmed intra-abdominal infections hospitalized in 24 neonatal intensive care units were studied in an open-label, multiple-dose study. Adverse events and serious adverse events were collected through 3 and 30 days following the last meropenem dose, respectively. Effectiveness was assessed by 3 criteria: death, bacterial cultures, and presumptive clinical cure score.Results.Of 200 subjects enrolled in the study, 99 (50) experienced an adverse event, and 34 (17) had serious adverse events; no adverse events were probably or definitely related to meropenem. The most commonly reported adverse events were sepsis (6), seizures (5), elevated conjugated bilirubin (5), and hypokalemia (5). Only 2 of the serious adverse events were determined to be possibly related to meropenem (isolated ileal perforation and an episode of fungal sepsis). Effectiveness was evaluable in 192 (96) subjects, and overall treatment success was 84.Conclusions.Meropenem was well tolerated in this cohort of critically ill infants, and the majority of infants treated with meropenem met the definition of therapeutic success.Clinical Trials Registration. NCT00621192.

Original languageEnglish
Pages (from-to)1495-1502
Number of pages8
JournalClinical Infectious Diseases
Volume55
Issue number11
DOIs
StatePublished - Dec 1 2012

Fingerprint

meropenem
Intraabdominal Infections
Safety
Sepsis
Hypokalemia
Neonatal Intensive Care Units
Bilirubin
Critical Illness
Premature Infants
Seizures

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Cohen-Wolkowiez, M., Poindexter, B., Bidegain, M., Weitkamp, J. H., Schelonka, R. L., Randolph, D. A., ... Smith, P. B. (2012). Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. Clinical Infectious Diseases, 55(11), 1495-1502. https://doi.org/10.1093/cid/cis758

Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. / Cohen-Wolkowiez, Michael; Poindexter, Brenda; Bidegain, Margarita; Weitkamp, Joern Hendrik; Schelonka, Robert L.; Randolph, David A.; Ward, Robert M.; Wade, Kelly; Valencia, Gloria; Burchfield, David; Arrieta, Antonio; Mehta, Varsha; Walsh, Michele; Kantak, Anand; Rasmussen, Maynard; Sullivan, Janice E.; Finer, Neil; Rich, Wade; Brozanski, Beverly S.; Van Den Anker, John; Blumer, Jeffrey; Laughon, Matthew; Watt, Kevin M.; Kearns, Gregory L.; Capparelli, Edmund V.; Martz, Karen; Berezny, Katherine; Benjamin, Daniel K.; Smith, P. Brian.

In: Clinical Infectious Diseases, Vol. 55, No. 11, 01.12.2012, p. 1495-1502.

Research output: Contribution to journalArticle

Cohen-Wolkowiez, M, Poindexter, B, Bidegain, M, Weitkamp, JH, Schelonka, RL, Randolph, DA, Ward, RM, Wade, K, Valencia, G, Burchfield, D, Arrieta, A, Mehta, V, Walsh, M, Kantak, A, Rasmussen, M, Sullivan, JE, Finer, N, Rich, W, Brozanski, BS, Van Den Anker, J, Blumer, J, Laughon, M, Watt, KM, Kearns, GL, Capparelli, EV, Martz, K, Berezny, K, Benjamin, DK & Smith, PB 2012, 'Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections', Clinical Infectious Diseases, vol. 55, no. 11, pp. 1495-1502. https://doi.org/10.1093/cid/cis758
Cohen-Wolkowiez M, Poindexter B, Bidegain M, Weitkamp JH, Schelonka RL, Randolph DA et al. Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. Clinical Infectious Diseases. 2012 Dec 1;55(11):1495-1502. https://doi.org/10.1093/cid/cis758
Cohen-Wolkowiez, Michael ; Poindexter, Brenda ; Bidegain, Margarita ; Weitkamp, Joern Hendrik ; Schelonka, Robert L. ; Randolph, David A. ; Ward, Robert M. ; Wade, Kelly ; Valencia, Gloria ; Burchfield, David ; Arrieta, Antonio ; Mehta, Varsha ; Walsh, Michele ; Kantak, Anand ; Rasmussen, Maynard ; Sullivan, Janice E. ; Finer, Neil ; Rich, Wade ; Brozanski, Beverly S. ; Van Den Anker, John ; Blumer, Jeffrey ; Laughon, Matthew ; Watt, Kevin M. ; Kearns, Gregory L. ; Capparelli, Edmund V. ; Martz, Karen ; Berezny, Katherine ; Benjamin, Daniel K. ; Smith, P. Brian. / Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. In: Clinical Infectious Diseases. 2012 ; Vol. 55, No. 11. pp. 1495-1502.
@article{3bb66eb16fef4e11a20f2da95abe6262,
title = "Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections",
abstract = "Background.Intra-abdominal infections are common in young infants and lead to significant morbidity and mortality. Meropenem is a broad-spectrum antimicrobial with excellent activity against pathogens associated with intra-abdominal infections. The purpose of this study was to determine the safety and effectiveness of meropenem in young infants with suspected or complicated intra-abdominal infections.Methods.Preterm and term infants <91 days of age with suspected or confirmed intra-abdominal infections hospitalized in 24 neonatal intensive care units were studied in an open-label, multiple-dose study. Adverse events and serious adverse events were collected through 3 and 30 days following the last meropenem dose, respectively. Effectiveness was assessed by 3 criteria: death, bacterial cultures, and presumptive clinical cure score.Results.Of 200 subjects enrolled in the study, 99 (50) experienced an adverse event, and 34 (17) had serious adverse events; no adverse events were probably or definitely related to meropenem. The most commonly reported adverse events were sepsis (6), seizures (5), elevated conjugated bilirubin (5), and hypokalemia (5). Only 2 of the serious adverse events were determined to be possibly related to meropenem (isolated ileal perforation and an episode of fungal sepsis). Effectiveness was evaluable in 192 (96) subjects, and overall treatment success was 84.Conclusions.Meropenem was well tolerated in this cohort of critically ill infants, and the majority of infants treated with meropenem met the definition of therapeutic success.Clinical Trials Registration. NCT00621192.",
author = "Michael Cohen-Wolkowiez and Brenda Poindexter and Margarita Bidegain and Weitkamp, {Joern Hendrik} and Schelonka, {Robert L.} and Randolph, {David A.} and Ward, {Robert M.} and Kelly Wade and Gloria Valencia and David Burchfield and Antonio Arrieta and Varsha Mehta and Michele Walsh and Anand Kantak and Maynard Rasmussen and Sullivan, {Janice E.} and Neil Finer and Wade Rich and Brozanski, {Beverly S.} and {Van Den Anker}, John and Jeffrey Blumer and Matthew Laughon and Watt, {Kevin M.} and Kearns, {Gregory L.} and Capparelli, {Edmund V.} and Karen Martz and Katherine Berezny and Benjamin, {Daniel K.} and Smith, {P. Brian}",
year = "2012",
month = "12",
day = "1",
doi = "10.1093/cid/cis758",
language = "English",
volume = "55",
pages = "1495--1502",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections

AU - Cohen-Wolkowiez, Michael

AU - Poindexter, Brenda

AU - Bidegain, Margarita

AU - Weitkamp, Joern Hendrik

AU - Schelonka, Robert L.

AU - Randolph, David A.

AU - Ward, Robert M.

AU - Wade, Kelly

AU - Valencia, Gloria

AU - Burchfield, David

AU - Arrieta, Antonio

AU - Mehta, Varsha

AU - Walsh, Michele

AU - Kantak, Anand

AU - Rasmussen, Maynard

AU - Sullivan, Janice E.

AU - Finer, Neil

AU - Rich, Wade

AU - Brozanski, Beverly S.

AU - Van Den Anker, John

AU - Blumer, Jeffrey

AU - Laughon, Matthew

AU - Watt, Kevin M.

AU - Kearns, Gregory L.

AU - Capparelli, Edmund V.

AU - Martz, Karen

AU - Berezny, Katherine

AU - Benjamin, Daniel K.

AU - Smith, P. Brian

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Background.Intra-abdominal infections are common in young infants and lead to significant morbidity and mortality. Meropenem is a broad-spectrum antimicrobial with excellent activity against pathogens associated with intra-abdominal infections. The purpose of this study was to determine the safety and effectiveness of meropenem in young infants with suspected or complicated intra-abdominal infections.Methods.Preterm and term infants <91 days of age with suspected or confirmed intra-abdominal infections hospitalized in 24 neonatal intensive care units were studied in an open-label, multiple-dose study. Adverse events and serious adverse events were collected through 3 and 30 days following the last meropenem dose, respectively. Effectiveness was assessed by 3 criteria: death, bacterial cultures, and presumptive clinical cure score.Results.Of 200 subjects enrolled in the study, 99 (50) experienced an adverse event, and 34 (17) had serious adverse events; no adverse events were probably or definitely related to meropenem. The most commonly reported adverse events were sepsis (6), seizures (5), elevated conjugated bilirubin (5), and hypokalemia (5). Only 2 of the serious adverse events were determined to be possibly related to meropenem (isolated ileal perforation and an episode of fungal sepsis). Effectiveness was evaluable in 192 (96) subjects, and overall treatment success was 84.Conclusions.Meropenem was well tolerated in this cohort of critically ill infants, and the majority of infants treated with meropenem met the definition of therapeutic success.Clinical Trials Registration. NCT00621192.

AB - Background.Intra-abdominal infections are common in young infants and lead to significant morbidity and mortality. Meropenem is a broad-spectrum antimicrobial with excellent activity against pathogens associated with intra-abdominal infections. The purpose of this study was to determine the safety and effectiveness of meropenem in young infants with suspected or complicated intra-abdominal infections.Methods.Preterm and term infants <91 days of age with suspected or confirmed intra-abdominal infections hospitalized in 24 neonatal intensive care units were studied in an open-label, multiple-dose study. Adverse events and serious adverse events were collected through 3 and 30 days following the last meropenem dose, respectively. Effectiveness was assessed by 3 criteria: death, bacterial cultures, and presumptive clinical cure score.Results.Of 200 subjects enrolled in the study, 99 (50) experienced an adverse event, and 34 (17) had serious adverse events; no adverse events were probably or definitely related to meropenem. The most commonly reported adverse events were sepsis (6), seizures (5), elevated conjugated bilirubin (5), and hypokalemia (5). Only 2 of the serious adverse events were determined to be possibly related to meropenem (isolated ileal perforation and an episode of fungal sepsis). Effectiveness was evaluable in 192 (96) subjects, and overall treatment success was 84.Conclusions.Meropenem was well tolerated in this cohort of critically ill infants, and the majority of infants treated with meropenem met the definition of therapeutic success.Clinical Trials Registration. NCT00621192.

UR - http://www.scopus.com/inward/record.url?scp=84869070247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869070247&partnerID=8YFLogxK

U2 - 10.1093/cid/cis758

DO - 10.1093/cid/cis758

M3 - Article

C2 - 22955430

AN - SCOPUS:84869070247

VL - 55

SP - 1495

EP - 1502

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 11

ER -